| Drug General Information |
| Drug ID |
D0Y5CG
|
| Former ID |
DNC010042
|
| Drug Name |
1-(2-((3-fluorophenoxy)methyl)phenyl)piperazine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C17H19FN2O
|
| Canonical SMILES |
C1CN(CCN1)C2=CC=CC=C2COC3=CC(=CC=C3)F
|
| InChI |
1S/C17H19FN2O/c18-15-5-3-6-16(12-15)21-13-14-4-1-2-7-17(14)20-10-8-19-9-11-20/h1-7,12,19H,8-11,13H2
|
| InChIKey |
IGKKFJKUWPDJDR-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Sodium-dependent noradrenaline transporter |
Target Info |
Inhibitor |
[1]
|
|---|
| 5-hydroxytryptamine 1A receptor |
Target Info |
Inhibitor |
[1]
|
| Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Serotonergic synapsehsa04726:Serotonergic synapse
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesisP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
5HT1 type receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
5HT3 type receptor mediated signaling pathway
|
|
5HT4 type receptor mediated signaling pathway
|
|
Reactome
|
Na+/Cl- dependent neurotransmitter transportersR-HSA-390666:Serotonin receptors
|
|
G alpha (i) signalling events
|
|
WikiPathways
|
Monoamine Transport
|
|
NRF2 pathway
|
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP722:Serotonin HTR1 Group and FOS Pathway
|
|
SIDS Susceptibility Pathways
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP727:Monoamine Transport
|
|
Synaptic Vesicle Pathway
|
|
Serotonin Transporter Activity
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2009 Dec 1;19(23):6604-7. Epub 2009 Oct 12.Discovery and pharmacological characterization of aryl piperazine and piperidine ethers as dual acting norepinephrine reuptake inhibitors and 5-HT1A partial agonists. |
|---|
